metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
metastatic (mCRPC) - 1st line (L1) castration-resistant prostate cancer (CRPC) metastatic (mCRPC) - 1st line (L1)
versus placebo
	ipilimumab alone
	CA184-095, 2017 J Clin Oncol 2017; 35:40-47 NCT01057810	RCT	metastatic (mCRPC) - 1st line (L1)	ipilimumab	placebo	chemotherapy-naive patients with asymptomatic or minimally symptomatic mCRPC and no known visceral metastases	400 / 202	low	inconclusive	inconclusive 11 % increase in deaths (OS) (PE) suggested 33 % decrease in progression or deaths (PFS)
	CA184-043, 2014 Lancet Oncol 2014;15:700-12 NCT00861614	RCT	metastatic (mCRPC) - 1st line (L1)	Ipilimumab	placebo	men with at least one bone metastasis from castration-resistant prostate cancer that had progressed after docetaxel treatment treated following radiotherapy	399 / 400	low	inconclusive	inconclusive 15 % decrease in deaths (OS) (PE) suggested 30 % decrease in progression or deaths (PFS)